Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...
In this video, Aaron Mark Drucker, MD, ScM, FRCPC, discusses his talk on the relative efficacy of small molecule, oral JAK ...
In addition to BP, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, chronic spontaneous ...
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous ...
In early April 2026, Regeneron Pharmaceuticals received U.S. FDA approval to extend EYLEA HD dosing intervals up to every 20 ...
In this video, Kristin Sokol, MD, MPH, FAAAAI, FACAAI, discusses what’s new in the atopic dermatitis space, including recent approvals and therapies in the pipeline.
Regeneron Pharmaceuticals REGN announced that the FDA has approved extending dosing intervals of up to every 20 weeks for ...
Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results